Linvoseltamab data in AL amyloidosis could have ‘tremendous implications’

morningstar.com·May 28, 2026 · 1 g fa

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

morningstar.com·May 30, 2026 · 3 h fa

The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet

fiercepharma.com·May 27, 2026 · 2 g fa

ASCO preview: With expectations jacked up, Akeso's ivonescimab to face scrutiny in high-stakes plenary

fiercepharma.com·May 29, 2026 · 18 h fa

ASCO: After Takeda’s defeat, Dizal picks up baton to take on J&J in EGFR lung cancer subtype

morningstar.com·May 27, 2026 · 2 g fa

Nuvalent Announces Key Program and Business Updates, Strengthening Foundation for Global Leadership in ROS1- and ALK-positive NSCLC

morningstar.com·May 29, 2026 · 18 h fa

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

morningstar.com·May 29, 2026 · 18 h fa

Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma

fiercepharma.com·May 28, 2026 · 1 g fa

With Elahere building steam, AbbVie nets FDA nod for another ImmunoGen cancer asset

medpagetoday.com·May 29, 2026 · 16 h fa

Bispecific Antibody Boosts Survival in Relapsed/Refractory Multiple Myeloma